Boston Scientific has been granted a patent for a method and external device that delivers sub-perception stimulation to patients via an implantable stimulator. The system allows for scheduled stimulation boluses, with options for additional on-demand stimulation, aimed at addressing specific patient symptoms. GlobalData’s report on Boston Scientific gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Boston Scientific, Prosthetic cardiac valves was a key innovation area identified from patents. Boston Scientific's grant share as of June 2024 was 55%. Grant share is based on the ratio of number of grants to total number of patents.
Sub-perception stimulation method using an implantable device
The patent US12042656B2 outlines a method for delivering stimulation to patients through an implantable stimulator device in conjunction with an external device. The method involves determining specific stimulation parameters tailored to address the patient's symptoms. It features a graphical user interface that allows for scheduling of stimulation boluses, which consist of a defined duration of stimulation followed by off times where no stimulation occurs. Additionally, the interface provides an option for patients to request immediate, unscheduled stimulation boluses. The stimulation is primarily directed to the neural tissue, such as the spinal cord, and can be adjusted based on the patient's activity, which may be monitored using an integrated activity sensor.
The claims further specify that the scheduled boluses can vary in duration, with each bolus lasting at least three minutes and off times lasting thirty minutes or more. The stimulation is delivered in the form of periodic pulses, with parameters such as amplitude, pulse width, and frequency being adjustable. The frequency can be set to 10 kHz or lower, with options for constant current amplitude. The method also includes provisions for a lockout period to regulate the timing of additional unscheduled boluses, ensuring that they are only administered if a specified duration has elapsed since the last scheduled bolus. This comprehensive approach aims to enhance patient control over their stimulation therapy while ensuring effective management of their symptoms.
To know more about GlobalData’s detailed insights on Boston Scientific, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
